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Introduction
Participation in multi-coded sports events often involves travel to 
international destinations. In South Africa, multi-coded teams are se-
lected on a number of occasions during the year to participate in lo-
cal competitions (SA Games, SA Student Games); continental zonal 
competitions (Zone 6 Games); continental competitions (All Africa 
Games); and intercontinental competitions (Commonwealth Games, 
World Student Games and Olympic Games). 
A significant part of the preparations and tasks of a team 
physician includes the decisions regarding the medical supply kit.
2,12
 
Complete preparation requires the choice of medications in sufficient 
quantity to cater for most medical problems that are encountered in 
multi-coded team events.
4,5,8
 While the medical support structures 
of the host country might be able to supply an adequate quantity 
and variety of medications through a polyclinic pharmacy, it is often 
the case that the foreign country is unable to do so, or the labels 
and drug information might be presented in a foreign language.
10,11
 
Furthermore, issues with respect to quality control and possible 
contamination of substances require the composition of a medical 
kit of sufficient variety and quantity to allow for the management 
of the medical conditions encountered during travel to foreign 
destinations. 
Thus the choice of which compounds to include in such kit and at 
what quantities is often a perplexing challenge for the team physician. 
The aim of this report is to document the various medications and 
quantity usage of medications during the Olympic Games in Athens 
2004. A model is also presented to calculate the anticipated quantities 
of medications in future events.
Methods
Data were collected over 30 days, starting when the team arrived in 
Athens (1 Sept) until the end of the Olympic Games (30 Sept). All 
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and quantity of medications dispensed, were recorded in the 
pharmacy stock control book at the South African medical facility, 
2004 Olympic Games, Athens, Greece.  Retrospective review of 
patient files and medical encounter forms was also undertaken to 
check against the pharmacy stock control book to ensure com-
plete data capture of dispensed medications. 
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during the observation period. The units of medication consumed 
per travelling team member were calculated by dividing the num-
ber of units (tablets, capsules, tubes, inhalers, bottles and am-
poules) used during the trip by the total number of travelling team 
members. 
results. Complete records of medications included in the travel-
ling pharmacy are described. Quantities of medications included 
ranged from single units to 2 250 units and percentage use of 
various medications varied from 0% to 100% of stocks. Units per 
team member ranged from 0 to 9.43. Medications were consumed 
from all categories of agents.  The most utilised agents included 
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the analgesics, musculoskeletal and non-steroidal anti-inflamma-
tory agents as well as certain vitamin and mineral supplements.
conclusions. This study describes the consumption of pharma-
cological agents by the athletes and officials of Team South Africa 
during the Athens 2004 Olympic Games. It also provides a model 
to assist with the estimation of quantities of medications to be 
included in the travelling pharmacy for future international multi-
coded sports events.  
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medications dispensed, over this period to both athletes and officials 
were recorded by the attending team physicians in the pharmacy 
stock control book in the medical room of Team SA. The names of 
the medications, including the dosage and quantity of medications 
dispensed, were recorded.  Retrospective review of patient files and 
medical encounter forms was also undertaken to check against the 
pharmacy stock control book to ensure complete data capture of dis-
pensed medications.  
The pharmacological constituents of each medication as well as 
quantities of medications were forwarded to the medical authorities 
of the host country for importation clearance prior to leaving South 
Africa. Following completion of the travel, the above data were 
added to the database to allow the calculation of the percentage of 
medication stocks used. The units of medications per travelling team 
member were calculated by dividing the number of units (tablets, 
capsules, tubes, inhalers, bottles and ampoules) used during the trip 
by the total number of travelling team members. 
results 
A total of 159 team members travelled to Athens. The team com-
prised 107 athletes from 12 sports codes and 52 officials. Athletes 
were defined as the members of the team engaged in competition 
and officials were defined as team or athlete coaches, team manag-
ers, team technical staff, administration officials, medical staff and 
National Olympic Committee members.
The medical consultations conducted during the 30-day period 
are described elsewhere in this publication.
5
 The medications, active 
ingredients, dosage, and quantities of medications used, are shown 
in Tables I - IV. 
Table I lists the pharmacological agents in the categories 
of neurological preparations, local anaesthetics, analgesics, 
musculoskeletal agents, autacoids and corticoids, and 
cardiovascular agents. Table II lists the pharmacological agents 
of the respiratory system, ear nose and throat drugs and drugs to 
manage gastrointestinal complaints. Dermatological and ophthalmic 
preparations, antimicrobials and drugs to treat urogenital complaints 
are listed in Table III while Table IV lists vitamin, mineral and 
electrolyte supplements as well as the drugs used for emergency 
management. 
Quantities of medications ranged from single units to 2 250 units 
and percentage use of various medications varied from 0% to 100% 
of stocks. Units per team member ranged from 0 to 9.43. Medications 
were consumed from all categories of agents yet certain agents were 
used to a far greater extent. These agents included the analgesics, 
musculoskeletal and non-steroidal anti-inflammatory agents as well 
as certain vitamin and mineral supplements.
Discussion
The ‘travelling pharmacy’ of Team South Africa consists of two large 
metal crates-on-wheels to facilitate being pushed during travel as 
their weight is in excess of 150 kg per container. This pharmacy is 
passed from one medical team to another and is used for most of 
South Africa’s multi-coded team events, including student games, 
African Zonal Games, All Africa, Commonwealth and Olympic/Para-
lympic Games. The pharmacy stock is checked prior to each trip for 
expired agents, and remaining quantities of stock from the previous 
trip are determined. 
Of the many responsibilities of a team physician, the decision of 
which agents to take to an international destination to successfully 
manage a team of athletes and officials is perhaps one of the more 
difficult.
1
 The team physicians have to be prepared to manage any 
medical complaint that might occur in a team of 100 - 500 athletes 
and officials. Medical complaints in a squad of that size can be both 
diverse in nature and numerous. For example, it is not uncommon on 
a single trip to be expected to manage a minor outbreak of gastro-
enteritis, renal stones, myocardial infarction, diabetes complications, 
acute psychosis and a variety of musculoskeletal injuries. 
It is prudent to select a sufficient variety of agents and in sufficient 
quantities to be independent of the services provided by the host 
country. While host country services can be excellent and ‘state-
of-the-art’, they can vary greatly depending on their geographical 
location and the choice of available medications as selected by the 
local pharmacist.
10
 Furthermore, certain medications might simply 
not be available in the host country or stock might be limited, or there 
might be delays in accessing host polyclinic services, leading to a 
delay in patient management. In some countries, the constituents of 
certain common medications can vary and contamination of agents 
can also occur. Thus a comprehensive, sufficiently stocked medical 
supply kit is important.
Factors influencing the choice of which agents to include in 
the travelling pharmacy include: personal preference of the team 
physician(s); unused unexpired medications from the previous trip; 
the country of destination and the anticipated medical problems 
(e.g. travelling to an area where malaria is endemic would require 
certain choices and quantities of agents); the nature of the team and 
individual sports included in the programme (e.g. athletes involved in 
contact sports could require increased quantities of analgesics and 
anti-inflammatory agents);
7
 the legislation of the country of destination 
(e.g. stopayne is not permitted for importation into Australia); and 
sponsorship of products from various pharmaceutical companies.
Yet, estimation of quantities of these required agents is often 
difficult. The above list of medications provides the reader with the 
details of compounds included in the travelling pharmacy, the quantity 
taken, usage thereof and the number of units per team member 
consumed during the time of the Athens 2004 Olympic Games. This 
latter number (which appears in column number 7) in Tables I - IV 
is particularly useful as it can be multiplied by the total number of 
persons in any future travelling party, and provides the physician 
with an estimated quantity of required medication based on a 30-day 
period. If the travel period is shorter (e.g. 2 weeks, the amount can be 
halved or if the trip is 6 weeks the number can be multiplied by 1.5). 
Clearly, this factor provides a guide only and is likely to vary, based 
on the above-mentioned variables.   
Usage of the analgesics and non-steroidal anti-inflammatory 
agents warrants special mention. While choice of a certain 
preparation over another would depend on factors including time to 
onset of action, desired route of administration and preference of 
both physician and athlete, it is of interest to note the use of the total 
number of units of all anti-inflammatory and analgesic tablets (and 
patches). The total number of units per team member for both these 
agents is 2.2. Therefore for a team size of 300 members the total 
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number of doses of these agents would be 660 tablets/capsules/ 
patches of non-steroidal anti-inflammatory agents and 660 tablets 
capsules of analgesic compounds based on a 30-day trip. This figure 
does not include injectable agents, the usage of which is indicated 
in Table I. The true consumption of non-steroidal anti-inflammatory 
agents during this event was however somewhat underestimated 
in this calculation, as it does not take into account flurbiprofen 
patches and other transdermal anti-inflammatories dispensed by 
the physiotherapists, or self-medication by the athletes using their 
own medication supplies.
14
 It is thus apparent that double or triple-
dosing of these agents regularly occurs and as these agents are 
not without side-effects,
3,6,9
 it is important that good communication 
exists between the physicians and physiotherapist with respect 
to dispensing of non-steroidal anti-inflammatory agents, and that 
the athletes are educated with respect to judicious use of these 
medications.
13
 It is therefore suggested that dispensing of all 
medications is conducted by the team physicians only. Furthermore, 
dispensing of small quantities of these agents with frequent re-
evaluation of the patient is preferable to dispensing larger quantities 
in original packaging. Indeed, this recommendation extends to the 
use of all medicinal compounds listed and not only the analgesics 
and anti-inflammatory agents.         
In conclusion, this study describes the consumption of 
pharmacological agents by the athletes and officials of Team South 
Africa during the Athens 2004 Olympic Games. It also provides a 
model to be used as a tool to assist with the estimation of quantities 
of medications to be included in the travelling pharmacy for future 
international multi-coded sports events.  
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